Article
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Cancer letters - 10 Oct 2016
Tilio Martina, Gambini Valentina, Wang Junbiao, Garulli Chiara, Kalogris Cristina, Andreani Cristina, Bartolacci Caterina, Elexpuru Zabaleta Maria, Pietrella Lucia, Hysi Albana, Iezzi Manuela, Belletti Barbara, Orlando Fiorenza, Provinciali Mauro, Galeazzi Roberta, Marchini Cristina, Amici Augusto
Abstract excerpt
HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of Δ16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.